Capecitabine/irinotecan combination regimens in colorectal cancer.

Capecitabine/irinotecan combination regimens in colorectal cancer.

Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer. In an analysis of pooled results of two phase III studies, capecitabine provided advantages over intravenous fluorouracil (5-FU) plus leucovorin in patients with...

Full description

Bibliographic Details
Main Author:	Kerr, D
Format:	Journal article
Language:	English
Published:	2002

Similar Items

Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
by: Kerr, D
Published: (2002)

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
by: Rea, D, et al.
Published: (2005)

Capecitabine/irinotecan in coloreetal cancer: European early-phase data and planned trials
by: Kerr, D
Published: (2002)

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment.
by: Kerr, D
Published: (2008)

Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
by: Wachsberger, P, et al.
Published: (2009)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008)

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
by: Sabharwal, A, et al.
Published: (2010)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Kerr, R, et al.
Published: (2016)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Love, S, et al.
Published: (2016)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
by: Middleton, G, et al.
Published: (2013)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
by: Middleton, G, et al.
Published: (2013)

A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.
by: Markham, C, et al.
Published: (2003)

Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
by: Middleton, G, et al.
Published: (2011)

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
by: Seymour, M, et al.
Published: (2011)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
by: Seymour, M, et al.
Published: (2013)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
by: Seymour, M, et al.
Published: (2013)

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
by: Folprecht, G, et al.
Published: (2008)

Capecitabine: have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
by: Hale, J, et al.
Published: (2002)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
by: Midgley, R, et al.
Published: (2007)

COLORECTAL CANCER
by: Kerr, D
Published: (2010)

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
by: Yanagisawa, Y, et al.
Published: (2010)

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
by: Yanagisawa, Y, et al.
Published: (2010)

Colorectal cancer.
by: Nicum, S, et al.
Published: (2003)

Colorectal cancer
by: Nicum, S, et al.
Published: (2003)

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
by: Midgley, R, et al.
Published: (2012)

Immunotherapy for colorectal cancer.
by: Midgley, R, et al.
Published: (2003)

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
by: Maughan, T, et al.
Published: (2002)

Chemotherapy for colorectal cancer.
by: Nicum, S, et al.
Published: (2000)

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
by: Rosmarin, D, et al.
Published: (2014)

Adjuvant chemotherapy for colorectal cancer.
by: Kerr, D, et al.
Published: (1996)

Adjuvant therapy of colorectal cancer.
by: Midgley, R, et al.
Published: (2000)

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
by: Rosmarin, D, et al.
Published: (2015)

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
by: Rosmarin, D, et al.
Published: (2015)

Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
by: Midgley, R, et al.
Published: (2005)

Gene therapy for colorectal cancer.
by: Kerr, D, et al.
Published: (2003)